The article discusses the emerging field of AI-driven phage therapy, highlighting its potential to combat antibiotic-resistant bacteria. It explores the mechanisms through which bacteriophages can be engineered to target specific pathogens, offering a promising alternative to traditional antibiotics. The implications for public health and future research directions are also considered.

K.J. Muldoon, a premature infant from Philadelphia, has been treated with a personalized Crispr gene-editing therapy for a rare metabolic disease known as severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. This breakthrough treatment, tailored to address his specific genetic mutation, marks a significant advancement in the application of gene-editing technology.